Senate Files

Bills

S. 1097 119th Congress

Interagency Patent Coordination and Improvement Act of 2025

Latest action, Apr 10, 2025: Placed on Senate Legislative Calendar under General Orders. Calendar No. 41.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

4 cosponsors

Sponsored by Richard J. Durbin (Democrat). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
2 D · 2 R
  • Democrat
  • Republican
  • Independent
4 senators cosponsoring

Referred to: Senate: Judiciary Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

23 clientsQ1 2025Q3 2026

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)
7 reports
COUNCIL FOR INNOVATION PROMOTION (C4IP)
7 reports
COUNCIL FOR INNOVATION PROMOTION (C4IP)
RADIUS ADVOCACY, LLC
7 reports
JOHNSON & JOHNSON SERVICES INC
7 reports
NOVARTIS
7 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
7 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
CROSSROADS STRATEGIES, LLC
7 reports
TEVA PHARMACEUTICALS USA, INC.
FAEGRE DRINKER BIDDLE & REATH LLP
7 reports
THE CAMPAIGN FOR SUSTAINABLE RX PRICING
MEHLMAN CONSULTING, INC.
7 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION
6 reports
BLUE CROSS AND BLUE SHIELD ASSOCIATION
6 reports
BLUE CROSS AND BLUE SHIELD OF FLORIDA INC
6 reports
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)
WHITMER & WORRALL, LLC
6 reports
GSK (FKA GLAXOSMITHKLINE INC.)
6 reports
BCBSM INC
5 reports
All 25 of 30 clients
ClientLobbying firmReportsReports totalingFromToSenate
AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)7$70KQ1 2025Q3 2026yes
COUNCIL FOR INNOVATION PROMOTION (C4IP)7$590KQ1 2025Q3 2026yes
COUNCIL FOR INNOVATION PROMOTION (C4IP)RADIUS ADVOCACY, LLC7$0Q1 2025Q3 2026yes
JOHNSON & JOHNSON SERVICES INC7$15.5MQ1 2025Q3 2026yes
NOVARTIS7$14.0MQ1 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA7$64.5MQ1 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICACROSSROADS STRATEGIES, LLC7$0Q1 2025Q3 2026yes
TEVA PHARMACEUTICALS USA, INC.FAEGRE DRINKER BIDDLE & REATH LLP7$0Q1 2025Q3 2026yes
THE CAMPAIGN FOR SUSTAINABLE RX PRICINGMEHLMAN CONSULTING, INC.7$630KQ1 2025Q3 2026yes
BIOTECHNOLOGY INNOVATION ORGANIZATION6$10.3MQ1 2025Q3 2026yes
BLUE CROSS AND BLUE SHIELD ASSOCIATION6$7.5MQ4 2025Q3 2026yes
BLUE CROSS AND BLUE SHIELD OF FLORIDA INC6$600KQ4 2025Q3 2026yes
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)WHITMER & WORRALL, LLC6$300KQ1 2025Q2 2026yes
GSK (FKA GLAXOSMITHKLINE INC.)6$7.2MQ1 2025Q3 2026yes
BCBSM INC5$148KQ4 2025Q3 2026yes
GUIDEWELL MUTUAL HOLDING CORPORATION5$30KQ4 2025Q3 2026yes
ASSOCIATION OF THE UNITED STATES ARMY, (INC.)4$409KQ4 2025Q1 2026yes
CONSERVATIVES FOR PROPERTY RIGHTSELITE STRATEGIC SERVICES4$163KQ4 2025Q1 2026yes
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INCCOVINGTON & BURLING LLP4$0Q1 2025Q2 2026yes
ASSOCIATION FOR ACCESSIBLE MEDICINES3$2.1MQ2 2025Q1 2026yes
BLUECROSS BLUESHIELD OF TENNESSEE3$780KQ1 2026Q3 2026yes
INTELLECTUAL PROPERTY OWNERS ASSOCIATION3$140KQ1 2025Q3 2025yes
KAISER FOUNDATION HEALTH PLAN INC3$1.6MQ4 2025Q3 2025yes
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION3$9.5MQ1 2026Q3 2026yes
AARP2$11.8MQ1 2025Q2 2025yes